Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Five Things Facing Teva’s New CEO Richard Francis

Former Sandoz Head To Take Charge At Teva On 1 January 2023

Executive Summary

With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.

You may also be interested in...



Teva Names Former Sandoz CEO Francis To Replace Schultz Within Weeks

In just under six weeks Teva will have a new president and CEO, after former Sandoz chief Richard Francis was announced as Kåre Schultz’s replacement from the start of 2023.

Teva Targets Risperidone LAI In H1 2023 Following Earlier FDA Snub

Teva maintains that the clinical data package looks sounds for it and partner MedinCell’s proposed 505(b)(2) hybrid risperidone long-acting injectable product, as the firms look to muscle in on the multi-billion-dollar LAI schizophrenia market next year.

Teva’s New York Opioid Liability Climbs To $523m With Settlement Deal

Teva is on the hook to pay more than $300m to New York state over the next 18 years, in addition to $210m in damages already agreed under its proposed nationwide settlement deal, after settling claims with the New York Attorney General.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel